BioArctic AB (OSTO:BIOA B)
kr 238.4 5 (2.14%) Market Cap: 21.06 Bil Enterprise Value: 20.57 Bil PE Ratio: 0 PB Ratio: 21.21 GF Score: 55/100

Q3 2021 BioArctic AB Earnings Call Transcript

Oct 21, 2021 / 07:30AM GMT
Release Date Price: kr143.8 (-1.64%)
Operator

Hello, and welcome to the BioArctic webcast with teleconference. (Operator Instructions) Just to remind you, this conference call is being recorded. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Thank you, and good morning, and welcome to BioArctic's Third Quarter Report 2020. I I'm Gunilla Osswald and I'm the CEO of BioArctic. I will share this presentation with our CFO, Jan Mattsson. I think it has been a great quarter for BioArctic and lecanemab. Our partner, Eisai, has after discussions with the U.S. FDA initiated a rolling submission for an accelerated approval for lecanemab in the U.S.

If it gets approved, lecanemab could thereby potentially be helping patients even earlier than previously expected, and I will talk more about that in the presentation here today. Next slide, please. BioArctic is listed on nasdaq.com midcap, and this is our disclaimer. Next slide, please.

BioArctic is a unique Swedish

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot